[go: up one dir, main page]

EP1917958A3 - Improved HIV protease inhibitors pharmaceutical formulations - Google Patents

Improved HIV protease inhibitors pharmaceutical formulations Download PDF

Info

Publication number
EP1917958A3
EP1917958A3 EP07121429A EP07121429A EP1917958A3 EP 1917958 A3 EP1917958 A3 EP 1917958A3 EP 07121429 A EP07121429 A EP 07121429A EP 07121429 A EP07121429 A EP 07121429A EP 1917958 A3 EP1917958 A3 EP 1917958A3
Authority
EP
European Patent Office
Prior art keywords
hiv protease
pharmaceutical formulations
protease inhibitors
improved hiv
improved
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP07121429A
Other languages
German (de)
French (fr)
Other versions
EP1917958B1 (en
EP1917958A2 (en
Inventor
Laman Alani
Soumojeet Ghosh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abbott Laboratories
Original Assignee
Abbott Laboratories
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23936923&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EP1917958(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to EP10177365.3A priority Critical patent/EP2269591B1/en
Priority to EP07121429A priority patent/EP1917958B1/en
Priority to SI200031073T priority patent/SI1917958T1/en
Priority to DK10177365.3T priority patent/DK2269591T3/en
Application filed by Abbott Laboratories filed Critical Abbott Laboratories
Publication of EP1917958A2 publication Critical patent/EP1917958A2/en
Publication of EP1917958A3 publication Critical patent/EP1917958A3/en
Publication of EP1917958B1 publication Critical patent/EP1917958B1/en
Application granted granted Critical
Priority to CY20121100711T priority patent/CY1112995T1/en
Priority to CY20181100697T priority patent/CY1120408T1/en
Anticipated expiration legal-status Critical
Revoked legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Virology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyrrole Compounds (AREA)

Abstract

Improved pharmaceutical compositions are provided comprising one or more solubilized HIV protease inhibiting compounds having improved solubility properties in a medium and/or long chain fatty acid, or mixtures thereof, a pharmaceutically acceptable alcohol, and water.
EP07121429A 2000-01-19 2000-12-01 Improved HIV protease inhibitors pharmaceutical formulations Revoked EP1917958B1 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
EP10177365.3A EP2269591B1 (en) 2000-01-19 2000-12-01 Improved pharmaceutical formulations
EP07121429A EP1917958B1 (en) 2000-01-19 2000-12-01 Improved HIV protease inhibitors pharmaceutical formulations
SI200031073T SI1917958T1 (en) 2000-01-19 2000-12-01 Improved HIV protease inhibitors pharmaceutical formulations
DK10177365.3T DK2269591T3 (en) 2000-01-19 2000-12-01 IMPROVED PHARMACEUTICAL FORMULATIONS
CY20121100711T CY1112995T1 (en) 2000-01-19 2012-08-07 IMPROVED PHARMACEUTICAL FORMS OF HIV PROTECTION ANSWERS
CY20181100697T CY1120408T1 (en) 2000-01-19 2018-07-03 IMPROVED PHARMACEUTICAL FORMS

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US48773900A 2000-01-19 2000-01-19
EP00982360A EP1248600B1 (en) 2000-01-19 2000-12-01 Improved hiv protease inhibitors pharmaceutical formulations
EP07121429A EP1917958B1 (en) 2000-01-19 2000-12-01 Improved HIV protease inhibitors pharmaceutical formulations

Related Parent Applications (2)

Application Number Title Priority Date Filing Date
EP00982360.0 Division 2000-12-01
EP00982360A Division EP1248600B1 (en) 2000-01-19 2000-12-01 Improved hiv protease inhibitors pharmaceutical formulations

Related Child Applications (2)

Application Number Title Priority Date Filing Date
EP10177365.3A Division EP2269591B1 (en) 2000-01-19 2000-12-01 Improved pharmaceutical formulations
EP10177365.3 Division-Into 2010-09-17

Publications (3)

Publication Number Publication Date
EP1917958A2 EP1917958A2 (en) 2008-05-07
EP1917958A3 true EP1917958A3 (en) 2008-08-27
EP1917958B1 EP1917958B1 (en) 2012-06-13

Family

ID=23936923

Family Applications (3)

Application Number Title Priority Date Filing Date
EP10177365.3A Revoked EP2269591B1 (en) 2000-01-19 2000-12-01 Improved pharmaceutical formulations
EP00982360A Revoked EP1248600B1 (en) 2000-01-19 2000-12-01 Improved hiv protease inhibitors pharmaceutical formulations
EP07121429A Revoked EP1917958B1 (en) 2000-01-19 2000-12-01 Improved HIV protease inhibitors pharmaceutical formulations

Family Applications Before (2)

Application Number Title Priority Date Filing Date
EP10177365.3A Revoked EP2269591B1 (en) 2000-01-19 2000-12-01 Improved pharmaceutical formulations
EP00982360A Revoked EP1248600B1 (en) 2000-01-19 2000-12-01 Improved hiv protease inhibitors pharmaceutical formulations

Country Status (26)

Country Link
EP (3) EP2269591B1 (en)
JP (1) JP4769400B2 (en)
KR (1) KR100861885B1 (en)
CN (1) CN100536833C (en)
AT (1) ATE395049T1 (en)
AU (2) AU1940501A (en)
BG (1) BG66112B1 (en)
BR (1) BR0011864A (en)
CA (1) CA2395987C (en)
CY (3) CY1108197T1 (en)
CZ (1) CZ304118B6 (en)
DE (1) DE60038899D1 (en)
DK (3) DK1917958T3 (en)
ES (3) ES2387579T3 (en)
HK (1) HK1120213A1 (en)
HU (1) HU229778B1 (en)
IL (2) IL150265A0 (en)
MX (1) MXPA02007097A (en)
NO (1) NO331400B1 (en)
NZ (1) NZ519724A (en)
PT (3) PT2269591T (en)
SI (3) SI1917958T1 (en)
SK (1) SK287143B6 (en)
TR (1) TR201809435T4 (en)
WO (1) WO2001052821A1 (en)
ZA (1) ZA200205109B (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5767429B2 (en) 1999-11-12 2015-08-19 アッヴィ・インコーポレイテッド Crystallization inhibitors in solid dispersants
US7364752B1 (en) 1999-11-12 2008-04-29 Abbott Laboratories Solid dispersion pharamaceutical formulations
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
GB0615211D0 (en) * 2006-07-31 2006-09-06 Ge Healthcare Uk Ltd Asymmetric flouro-substituted polymethine dyes
WO2009019661A1 (en) * 2007-08-07 2009-02-12 Ranbaxy Laboratories Limited Process for preparation of amorphous lopinavir
WO2012164575A2 (en) 2011-05-27 2012-12-06 Hetero Research Foundation Amorphous ritonavir co-precipitated
GB201808564D0 (en) 2018-05-24 2018-07-11 Douglas Pharmaceuticals Ltd Treatments
GB201808563D0 (en) 2018-05-24 2018-07-11 Univ Manchester Treatments

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998022106A1 (en) * 1996-11-21 1998-05-28 Abbott Laboratories Pharmaceutical composition
WO2000074677A2 (en) * 1999-06-04 2000-12-14 Abbott Laboratories Improved pharmaceutical formulations

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US594836A (en) * 1897-11-30 Corner-brace
US5539122A (en) 1989-05-23 1996-07-23 Abbott Laboratories Retroviral protease inhibiting compounds
US5354866A (en) 1989-05-23 1994-10-11 Abbott Laboratories Retroviral protease inhibiting compounds
GB8927913D0 (en) 1989-12-11 1990-02-14 Hoffmann La Roche Amino acid derivatives
DE69130070T2 (en) 1990-11-19 1999-04-29 Monsanto Co., St. Louis, Mo. RETROVIRAL PROTEASE INHIBITORS
CA2056911C (en) 1990-12-11 1998-09-22 Yuuichi Nagano Hiv protease inhibitors
EP0532466A3 (en) 1991-09-12 1993-06-16 Ciba-Geigy Ag Derivatives of 5-amino-4-hydroxy-hexanoic acid and their therapeutical use
AU2871592A (en) 1991-10-11 1993-05-03 Du Pont Merck Pharmaceutical Company, The Cyclic ureas and analogues useful as retroviral protease inhibitiors
US5413999A (en) 1991-11-08 1995-05-09 Merck & Co., Inc. HIV protease inhibitors useful for the treatment of AIDS
ES2112880T3 (en) 1991-11-08 1998-04-16 Merck & Co Inc HIV PROTEASE INHIBITORS USEFUL FOR AIDS TREATMENT.
EP0560268B1 (en) 1992-03-13 1995-01-04 Bio-Mega/Boehringer Ingelheim Research Inc. Substituted pipecolinic acid derivatives as HIV protease inhibitors
WO1993023368A1 (en) 1992-05-20 1993-11-25 G.D. Searle & Co. Urea-containing hydroxyethylamine compounds as retroviral protease inhibitors
US5559256A (en) 1992-07-20 1996-09-24 E. R. Squibb & Sons, Inc. Aminediol protease inhibitors
IS2334B (en) 1992-09-08 2008-02-15 Vertex Pharmaceuticals Inc., (A Massachusetts Corporation) Aspartyl protease inhibitor of a new class of sulfonamides
US5484926A (en) 1993-10-07 1996-01-16 Agouron Pharmaceuticals, Inc. HIV protease inhibitors
WO1994014436A1 (en) 1992-12-29 1994-07-07 Abbott Laboratories Retroviral protease inhibiting compounds
AU7518694A (en) 1993-08-20 1995-03-21 G.D. Searle & Co. Retroviral protease inhibitors and combinations thereof
IL110752A (en) 1993-09-13 2000-07-26 Abbott Lab Liquid semi-solid or solid pharmaceutical composition for an HIV protease inhibitor
US5559158A (en) 1993-10-01 1996-09-24 Abbott Laboratories Pharmaceutical composition
US5491253A (en) 1993-10-22 1996-02-13 Abbott Laboratories Process for the preparation of a substituted 2,5-diamino-3-hydroxyhexane
IL111991A (en) * 1994-01-28 2000-07-26 Abbott Lab Liquid pharmaceutical composition of HIV protease inhibitors in organic solvent
IL129871A (en) 1994-05-06 2003-11-23 Pharmacia & Upjohn Inc Process for preparing 4-phenyl-substituted octanoyl-oxazolidin-2-one intermediates that are useful for preparing pyran-2-ones useful for treating retroviral infections
US5567823A (en) 1995-06-06 1996-10-22 Abbott Laboratories Process for the preparation of an HIV protease inhibiting compound
US6037157A (en) 1995-06-29 2000-03-14 Abbott Laboratories Method for improving pharmacokinetics
US5914332A (en) 1995-12-13 1999-06-22 Abbott Laboratories Retroviral protease inhibiting compounds
EP1295874A3 (en) * 1995-12-13 2003-04-02 Abbott Laboratories Retroviral protease inhibiting compounds
US6160122A (en) 1996-06-28 2000-12-12 Abbott Laboratories Process for the preparation of a disubstituted thiazole

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998022106A1 (en) * 1996-11-21 1998-05-28 Abbott Laboratories Pharmaceutical composition
WO2000074677A2 (en) * 1999-06-04 2000-12-14 Abbott Laboratories Improved pharmaceutical formulations

Also Published As

Publication number Publication date
NO20023455D0 (en) 2002-07-18
CZ304118B6 (en) 2013-11-06
WO2001052821A1 (en) 2001-07-26
EP1917958B1 (en) 2012-06-13
JP2003533435A (en) 2003-11-11
ATE395049T1 (en) 2008-05-15
AU2006235895A1 (en) 2006-11-30
DK2269591T3 (en) 2018-07-16
SI1248600T1 (en) 2008-08-31
CY1108197T1 (en) 2014-02-12
NZ519724A (en) 2004-07-30
HUP0302070A2 (en) 2003-09-29
AU2006235895B2 (en) 2009-08-13
MXPA02007097A (en) 2003-01-28
BG66112B1 (en) 2011-05-31
DE60038899D1 (en) 2008-06-26
EP1248600A1 (en) 2002-10-16
CY1120408T1 (en) 2019-07-10
NO20023455L (en) 2002-09-18
CY1112995T1 (en) 2016-04-13
BR0011864A (en) 2004-07-20
DK1917958T3 (en) 2012-09-24
SI2269591T1 (en) 2018-08-31
PT2269591T (en) 2018-07-09
ZA200205109B (en) 2003-10-31
SK11102002A3 (en) 2002-12-03
SK287143B6 (en) 2010-01-07
CZ20022663A3 (en) 2002-11-13
HK1120213A1 (en) 2009-03-27
JP4769400B2 (en) 2011-09-07
KR20020082210A (en) 2002-10-30
CN1424907A (en) 2003-06-18
IL150265A0 (en) 2002-12-01
DK1248600T3 (en) 2008-09-08
ES2676151T3 (en) 2018-07-17
TR201809435T4 (en) 2018-07-23
IL150265A (en) 2015-02-26
NO331400B1 (en) 2011-12-19
ES2304990T3 (en) 2008-11-01
HU229778B1 (en) 2014-07-28
SI1917958T1 (en) 2012-10-30
BG106976A (en) 2003-05-30
PT1917958E (en) 2012-08-16
KR100861885B1 (en) 2008-10-09
EP1917958A2 (en) 2008-05-07
EP2269591A3 (en) 2011-07-27
ES2387579T3 (en) 2012-09-26
PL361396A1 (en) 2004-10-04
EP2269591B1 (en) 2018-04-04
CN100536833C (en) 2009-09-09
AU1940501A (en) 2001-07-31
EP2269591A2 (en) 2011-01-05
CA2395987A1 (en) 2001-07-26
CA2395987C (en) 2009-12-22
PT1248600E (en) 2008-08-25
EP1248600B1 (en) 2008-05-14
HUP0302070A3 (en) 2007-02-28

Similar Documents

Publication Publication Date Title
BG106239A (en) Improved pharmaceutical formulations
HK1120213A1 (en) Improved hiv protease inhibitors pharmaceutical formulations
EP1767193A3 (en) Pharmaceutical compositions
EP2258345A3 (en) Solid pharmaceutical dosage form comprising an HIV protease inhibitor solid dispersion
HUP0300855A3 (en) Peptidmomimetic protease inhibitors, pharmaceutical compositions and their use
WO2002080976A3 (en) Hsa-free formulations of interferon-beta
MXPA03004941A (en) Drug formulation having improved oral tolerability.
MA26968A1 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING AMLODIPINE MALEATE.
HUP0400832A3 (en) New amidoalkyl-piperidine and amidoalkyl-piperazine derivatives, and pharmaceutical compositions containing such derivatives as active ingredients
CA2429639A1 (en) Stable azithromycin monohydrate
HUP9901887A2 (en) Compositions comprising an hiv protease inhibitor and a water soluble vitamin e compound
CA2368625A1 (en) Solubilizing aids in powder form for solid pharmaceutical presentation forms
SE0001916D0 (en) Novel formulation
AU2001272695A1 (en) Azithromocin monohydrate with lower hygroscopicity, preparation method and pharmaceutical compositions which include it
EP1157617A3 (en) Use of alpha-keto enamine derivatives as ingredients
EP1629845A3 (en) Use of cortisol-sequestering agents for the treatment of hypercortisolaemia related disorders
WO2002047723A1 (en) Medicinal compositions having improved water-solubility
ZA200205556B (en) Pharmaceutical compositions and their preparation.
CA2319609A1 (en) Oral liquid formulations of benzoxazinones hiv reverse transcriptase inhibitors
CY2444B1 (en) Compositions comprising an hiv protease inhibitor such as vx 478 and a water soluble vitamin e compound such as vitamin e-tpgs.

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AC Divisional application: reference to earlier application

Ref document number: 1248600

Country of ref document: EP

Kind code of ref document: P

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Extension state: RO SI

PUAL Search report despatched

Free format text: ORIGINAL CODE: 0009013

AK Designated contracting states

Kind code of ref document: A3

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Extension state: RO SI

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1120213

Country of ref document: HK

17P Request for examination filed

Effective date: 20090217

17Q First examination report despatched

Effective date: 20090318

AKX Designation fees paid

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AXX Extension fees paid

Extension state: RO

Payment date: 20090217

Extension state: SI

Payment date: 20090217

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: ABBOTT LABORATORIES

AC Divisional application: reference to earlier application

Ref document number: 1248600

Country of ref document: EP

Kind code of ref document: P

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Extension state: RO SI

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 561658

Country of ref document: AT

Kind code of ref document: T

Effective date: 20120615

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: NV

Representative=s name: BOHEST AG

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 60047283

Country of ref document: DE

Effective date: 20120809

REG Reference to a national code

Ref country code: PT

Ref legal event code: SC4A

Free format text: AVAILABILITY OF NATIONAL TRANSLATION

Effective date: 20120808

REG Reference to a national code

Ref country code: DK

Ref legal event code: T3

REG Reference to a national code

Ref country code: SE

Ref legal event code: TRGR

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2387579

Country of ref document: ES

Kind code of ref document: T3

Effective date: 20120926

Ref country code: NL

Ref legal event code: T3

REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1120213

Country of ref document: HK

REG Reference to a national code

Ref country code: GR

Ref legal event code: EP

Ref document number: 20120401771

Country of ref document: GR

Effective date: 20120920

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

REG Reference to a national code

Ref country code: PT

Ref legal event code: PC4A

Owner name: ABBVIE INC., US

Effective date: 20130410

26N No opposition filed

Effective date: 20130314

REG Reference to a national code

Ref country code: ES

Ref legal event code: PC2A

Owner name: ABBVIE INC.

Effective date: 20130624

Ref country code: ES

Ref legal event code: PC2A

Owner name: ABBVIE INC.

Effective date: 20130618

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 60047283

Country of ref document: DE

Effective date: 20130314

REG Reference to a national code

Ref country code: NL

Ref legal event code: SD

Effective date: 20130819

REG Reference to a national code

Ref country code: DE

Ref legal event code: R082

Ref document number: 60047283

Country of ref document: DE

Representative=s name: SCHIEBER - FARAGO, DE

REG Reference to a national code

Ref country code: GB

Ref legal event code: 732E

Free format text: REGISTERED BETWEEN 20130815 AND 20130821

REG Reference to a national code

Ref country code: CH

Ref legal event code: PUE

Owner name: ABBVIE INC., US

Free format text: FORMER OWNER: ABBOTT LABORATORIES, US

REG Reference to a national code

Ref country code: DE

Ref legal event code: R081

Ref document number: 60047283

Country of ref document: DE

Owner name: ABBVIE INC. (N.D.GES.D. STAATES DELAWARE), CHI, US

Free format text: FORMER OWNER: ABBOTT LABORATORIES, ABBOTT PARK, ILL., US

Effective date: 20130909

Ref country code: DE

Ref legal event code: R082

Ref document number: 60047283

Country of ref document: DE

Representative=s name: SCHIEBER - FARAGO, DE

Effective date: 20130909

Ref country code: DE

Ref legal event code: R081

Ref document number: 60047283

Country of ref document: DE

Owner name: ABBVIE INC. (N.D.GES.D. STAATES DELAWARE), US

Free format text: FORMER OWNER: ABBOTT LABORATORIES, ABBOTT PARK, US

Effective date: 20130909

Ref country code: DE

Ref legal event code: R082

Ref document number: 60047283

Country of ref document: DE

Representative=s name: FARAGO PATENTANWAELTE, DE

Effective date: 20130909

Ref country code: DE

Ref legal event code: R082

Ref document number: 60047283

Country of ref document: DE

Representative=s name: FARAGO PATENTANWALTS- UND RECHTSANWALTSGESELLS, DE

Effective date: 20130909

REG Reference to a national code

Ref country code: FR

Ref legal event code: TP

Owner name: ABBVIE INC., US

Effective date: 20130930

REG Reference to a national code

Ref country code: CH

Ref legal event code: PCAR

Free format text: NEW ADDRESS: HOLBEINSTRASSE 36-38, 4051 BASEL (CH)

REG Reference to a national code

Ref country code: SI

Ref legal event code: SP73

Owner name: ABBVIE INC.; US

Effective date: 20141118

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 16

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 17

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 18

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: LU

Payment date: 20190918

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SE

Payment date: 20191209

Year of fee payment: 20

Ref country code: DE

Payment date: 20191114

Year of fee payment: 20

Ref country code: IE

Payment date: 20191125

Year of fee payment: 20

Ref country code: MC

Payment date: 20191127

Year of fee payment: 20

Ref country code: FI

Payment date: 20191125

Year of fee payment: 20

Ref country code: CY

Payment date: 20191021

Year of fee payment: 20

Ref country code: NL

Payment date: 20191127

Year of fee payment: 20

Ref country code: PT

Payment date: 20191127

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: BE

Payment date: 20191119

Year of fee payment: 20

Ref country code: FR

Payment date: 20191122

Year of fee payment: 20

Ref country code: GR

Payment date: 20191125

Year of fee payment: 20

Ref country code: IT

Payment date: 20191218

Year of fee payment: 20

Ref country code: DK

Payment date: 20191125

Year of fee payment: 20

REG Reference to a national code

Ref country code: DE

Ref legal event code: R061

Ref document number: 60047283

Country of ref document: DE

PLBR Kind of request for revocation recorded

Free format text: ORIGINAL CODE: EPIDOSNRVR2

PLBT Request for revocation filed by patent holder

Free format text: ORIGINAL CODE: EPIDOSNRVR1

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: AT

Payment date: 20191125

Year of fee payment: 20

Ref country code: TR

Payment date: 20191126

Year of fee payment: 20

Ref country code: CH

Payment date: 20191028

Year of fee payment: 20

PLDH Decision on request for revocation

Free format text: ORIGINAL CODE: EPIDOSNRVR3

RDAA Patent revoked on request of proprietor

Free format text: ORIGINAL CODE: 0009220

PLBU Request for revocation filed by patent holder

Free format text: ORIGINAL CODE: EPIDOSNRVR6

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: PATENT REVOKED BY PROPRIETOR

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20200102

Year of fee payment: 20

Ref country code: GB

Payment date: 20191126

Year of fee payment: 20

RVAA Request for revocation filed after opposition period found admissible

Filing date: 20200326

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

REG Reference to a national code

Ref country code: DE

Ref legal event code: R071

Ref document number: 60047283

Country of ref document: DE

REG Reference to a national code

Ref country code: NL

Ref legal event code: MK

Effective date: 20201130

REG Reference to a national code

Ref country code: DK

Ref legal event code: EUP

Expiry date: 20201201

REG Reference to a national code

Ref country code: GB

Ref legal event code: PE20

Expiry date: 20201130

Ref country code: IE

Ref legal event code: MK9A

REG Reference to a national code

Ref country code: FI

Ref legal event code: MAE

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK07

Ref document number: 561658

Country of ref document: AT

Kind code of ref document: T

Effective date: 20201201

REG Reference to a national code

Ref country code: BE

Ref legal event code: MK

Effective date: 20201201

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20210309

REG Reference to a national code

Ref country code: SE

Ref legal event code: EUG